TY  - JOUR
AU  - López-Sanromán, Antonio
AU  - Vera-Mendoza, Isabel
AU  - Domènech, Eugeni
AU  - Taxonera, Carlos
AU  - Vega Ruiz, Vicente
AU  - Marín-Jiménez, Ignacio
AU  - Guardiola, Jordi
AU  - Castro, Luisa
AU  - Esteve, María
AU  - Iglesias, Eva
AU  - Ceballos, Daniel
AU  - Martínez-Montiel, Pilar
AU  - Gisbert, Javier P
AU  - Mínguez, Miguel
AU  - Echarri, Ana
AU  - Calvet, Xavier
AU  - Barrio, Jesús
AU  - Hinojosa, Joaquín
AU  - Martín-Arranz, María Dolores
AU  - Márquez-Mosquera, Lucía
AU  - Bermejo, Fernando
AU  - Rimola, Jordi
AU  - Pons, Vicente
AU  - Nos, Pilar
AU  - Spanish GETECCU group [APPRECIA                    study]
PY  - 2017
DO  - 10.1093/ecco-jcc/jjx051
UR  - http://hdl.handle.net/10668/11087
T2  - Journal of Crohn's & colitis
AB  - Postoperative recurrence of Crohn's disease [POR-CD] is almost certain if no prophylaxis is administered. Evidence for optimal treatment is lacking. Our aim was to compare the efficacy of adalimumab [ADA] and azathioprine [AZA] in this setting. We...
LA  - en
KW  - Crohn’s disease
KW  - adalimumab
KW  - azathioprine
KW  - Adalimumab
KW  - Adult
KW  - Azathioprine
KW  - Crohn Disease
KW  - Female
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Male
KW  - Postoperative Care
KW  - Secondary Prevention
TI  - Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.
TY  - research article
VL  - 11
ER  -